Member Info for The_Paladin

Thank you Kane. That X message, together with a long string of other IB posts sums up the retail investors’ dilemma. We seem to be invested in a very credible and creative micro company with great potential. Why isn’t this reflected in the share price? Yesterday, we saw over 1% of the company’s shares sold in a day for a pittance. The share price correspondingly fell by >9% to the point that it is close to the all-time low value, which was also reached recently.

Why did yesterday’s sell off happen? The seller(s) was/were evidently not seriously invested in IQ-AI. The recent GaM trial update, and Kane’s summary X message suggest that IB has considerable potential.

Why then dump more than 1% of the company for a miserly sum, and further reduce the share price? This is not the action of a someone with a real interest in IQ-AI. It remains a worrying time for long term retail investors.

Fair point Tyke. Thank you.

For sure though, what we have seen, since I have been invested, is not an acceptable template for running a company with noble aspirations. Let us hope that the undoubted quality in IB’s work and eventually bears fruit for all concerned.

GLA,

Another DELIBERATE unexpected selloff of 2,209,606 shares to date today, in a short spell, taking the share price back into all-time low territory. An apalling year to date for IQ-AI, following a terrible 2024. None of this tallies with the last RNS,for which we might have reasonably expected a sustained rise in the share price?

The recent placement could only have been to cover IQ-AI execs' wages and expenses. Our best information suggests that IB is self-sustaining?

When are the CEO and his team going to bring about some measures to effect a positive impact? Clearly, his family's selloff of their entire shareholding destroyed the share price, and, with it, market confidence in this company! IB's continuous positive messages about the GaM trial, and the quality of their diagnostics, are alone insufficient to impress prospective investors!

Thank you howdlep. I fully concur.

The potential of this investment has been in plain sight for years. I have remained invested, but the expected growth hasn’t happened? I am at a loss to explain why not?

I am also grateful to max for continuously updating this forum on the latest IB news. Someone on here compared once our situation with Amazon, which remained under investors’ radar for a long time before its potential was finally noticed. Are there parallels to be drawn here?

What will it take for IB’s excellent work to attract investment from a large entity? The current MCap of around £2m must be considerably below true valuation, when one considers the value of the IP attached to IB’s products alone? There is also the outcome of the GaM Ph1 trial, and its consequences to consider.

Surely TB’s market activity cannot be entirely to blame for our current position, although it hasn’t helped the investment case. All investors can but hope that IQ-AI will henceforth be fully focused in raising awareness of the enormous potential that IB offers, and finally attract some significant attention and support?

Yesterday’s small gain through several trades at a consistent level has been cancelled by a single large-ish trade this morning.

We are in need of significant news to add stability to the share price, and promote more buys. The month of May is rapidly approaching. Does the “Sell in May, and go away” rule apply here? Unfortunately the recent placement suggests to me that significant news is unlikely to happen for the time being?

But, who am I to know anything? My lack of understanding was exposed by my 4+ years of holding shares in a rogue company, with a less than competent CEO at the helm!

Yes, SNG is the company I was referring to. The SNG execs and BOD paid themselves high salaries, from the residue of the funds raised for a catastrophic trial, - for three long years. In that time, they achieved nothing whatsoever!

To our benefit here, there is a far higher level of competence, and more transparency from IB, than investors were ever shown by SNG. I am hopeful of an eventual beneficial outcome for everyone involved here, retail investors in particular.

Good morning Laura.

Thank you. I do not have access to that information.

The rise to a significant share price (600-700% to return to Dec 2023 levels) will only be possible if we receive a concrete update from the company. By this I mean news of a substantial increase in revenue from product sales, or a promising outcome from the Phase 1 GaM trial. The latter could result in one of several outcomes, which might benefit the company.

Any progress will depend on the implementation of beneficial measures for the good of the company from the CEO and Board. Unfortunately, CEO’s actions in particular don’t always benefited retail investors.

My recent experience concerning a rogue CEO from another company - a “Judge me at the EGM” comment, which led to the wipeout of all retail investors, has led to a high degree of mistrust in CEOs in particular. Hopefully, we won’t see anything similar happening here?

The London Stock Exchange is quoting 0.77/0.83 at a share price of 0.8p. My broker values my stock at the current share price. They usually quote a significantly lower price. Does this indicate buying pressure ahead? Let’s hope so, as we have only experienced share price decline to date this year. Market confidence has been low since the CEO and his family offloaded their shareholding. A MCap of £10m, as was the case at the time, would surely represent “fair” value at the moment, when one considers what the company has to offer?

I am surprised that large entities are not looking at adding our imaging technology incorporating AI to their portfolio? I should add that many including myself had similar thoughts about a small biopharmaceutical company, which recently kicked their retail investors in the backside. Hopefully, we won’t experience a similar outcome here, but one never knows?

I am hoping for a return to a higher share price in the near future. The current MCap makes no sense whatsoever. The recent information concerning IB’s high definition tumour imaging underpinned by AI driven diagnostics, and the progress made in the GaM trial, suggests that the company is undervalued.

Unfortunately, this is contradicted by the recent placement, which literally halved the share price from an already low level of 1.4p. The CEO and Board would not be raising funds, presumably to pay their salaries and other company expenses, if there was imminent news to the company’s advantage on the horizon?

Currently, the sell price for 50K shares is 0.751p. Is this the bottom? Were they recent sells partly to do with the fact that we are nearing the end of the financial year? Were recent purchasers of IQAI stock disposing of it due to lack of progress? Perhaps the issuing of 25m new shares for a tiny amount prompted the sells?

I can but speculate because I don’t know. Like others here, I can but hope that the investments of long term retail investors are part of this company’s future plans. Having seen the shabby treatment recently dispensed on LTIs by another tiny company recently, I remain wary! GLA.

“revenue” not “revenge”.

Today’s first trade suggests that the share dumping is continuing and that a lower share price beckons?

An excellent summary howdlep, as always. I am aware from your previous posts that your research is detailed and thorough.

I agree that TB’s activities are currently determining the course of this company. It would appear that he is focused on benefiting himself, and his associates, apparently to the detriment of retail investors? It is probably time for him to step down.

MS would be an ideal replacement, as the future of the company rests on what IB is able to achieve. I have little information about IB’s revenue and projected future growth. Currently it rests on the sales of its diagnostic products; hopefully they are going down a licensing route, to generate continued revenge for future upgrades to their software?

I appreciate that the GaM trial is another iron in the fire. As is the case with clinical trials, it is taking a long time to complete the Ph1 stage. It seems likely that it will subsequently progress to a Ph2 trial. Hopefully, TB will not be involved at the Ph2 funding stage. Past precedent suggests that he might work it to his own advantage, with a massive share dilution to the detriment of current retail investors?

Unfortunately, I recently lost a lot of capital in a biopharmaceutical company, which was totally mismanaged by an incompetent CEO, and inexperienced CSO. The executives of IQAI are nowhere near that category, but I am more wary than before. As an investor, it is my view that it is high time that we were given some evidence of progress in IB’s promising initiatives. As said previously, the newsletters and X messages are indicative of progress, but add no value. Hopefully, some indication of future revenue growth will be forthcoming? GLA

Unfortunately, the company’s overall lack of activity during the last 18 months has resulted in a hugely depleted share price, and a negative sentiment.

advfn are now producing AI produced summaries of contributors comments on their investor chat forums. Here is the recent one for IQ-AI:

“Recent investor discussions regarding IQAI (Iq-ai Limited) have highlighted a concerning sentiment among shareholders. Notable comments, such as "Yep, this one is dead in the water," emphasize a growing pessimism regarding the stock's performance. Investors appear to be bracing for declines, with one user expressing a "sinking feeling" as the stock approaches a low of 0.0075. There is also speculation about increased selling activity leading up to the end of the tax year, which could add to the downward pressure on the stock price.

Overall, the financial highlights from these discussions indicate a lack of confidence in the company’s future prospects, with many investors voicing doubts about the stock's ability to recover. Critical insights reveal an overarching fear of further depredation in stock value, aligning with recent trends and overall investor sentiment that leans towards cautious pessimism. Such discussions serve as a reflection of the broader challenges faced by IQAI in the market landscape.”

The selling continues, at new 52-week low share prices. If what we are being told by IB is correct, there is no logical explanation for this?

Is last week’s placement going to result in halving the share price ( to 0.7p) from last Monday’s 52-week low?

It is high time for the company to get a grip! Positive newsletters, and regular X posts with high definition state of the art images of tumours are having no impact at present! We are more like a very early stage University spinoff, than a company en route to growth and profitable activity?

Some fair points were made by semantic regarding the recent placement. I am convinced though that such a small sum will only serve to cover the company’s basic running costs for another year. The claims made regarding the allocation of these funds doesn’t tally with me. There simply isn’t enough capital to disseminate significant sums between our areas needing development.

On a more positive note, having re-read the information concerning the company’s innovative products, and the GaM trial, I strongly agree with others that IQ-AI/IB is significantly undervalued by the market at present.

One further point. Whatever happened to Stone Checker? Little has been documented about it in recent years?

https://healthairegister.com/products/imaging-biometrics-stonechecker/

Will it be further enhanced? Does it have a future as a part of the company’s repertoire of advanced diagnostic technologies ?

Evidently, more shenanigans as a consequence of the way that IQ-AI is run? Although not an AIM company, IQ-AI is apparently being run for the benefit of the CEO and his associates? It is a disgrace that they are continuously allowed to get away with this!

The share price is currently at around 40% of its value at the start of the year. Its value at the start of the year was around 40% of the peak value going into 2024. A case of ever decreasing circles!

A poor AIM company in all but designation. Despite all the positive news issued earlier this year, the share price decline has been disastrous for long term retail investors.

I find it difficult to reconcile our potential both from the imaging perspective, and from the anticipated GaM trial update with IQ-AI’s current MCap? Surely our IP involving advanced imaging technology linked to AI diagnostics has inherent value? This is not reflected in the share price.

Further, the fragility of the share price following the placement RNS has led to a 50% share price collapse and the third 52-week low in less than a week yesterday.

As an investor, I find this concerning. There was nothing in the company’s statements earlier this year that suggested yet further significant decline following last year’s shenanigans.

I hope that the CEO and Board will address this situation soon, and provide the market with detailed statements predicting further growth in our revenue that are now needed. It seems to me that I may have totally misjudged this company’s potenti? Hopefully not?

The share price has crashed from an already low price of 1.9p on Jan 25 to 0.95 - 0.96p this morning. A 50% decline in less than two months following three optimistic RNS statements this year? Two 52-week low prices were achieved on successive days this week following the RNS. There is nothing to contradict the possibility that the share price may continue to fall today?

The cash raise barely covers the salaries of “executives” and directors’ expenses if that? The CEO needs to address investors, and inform us in detail what is actually going on inside this company. The vague rationale given in Peterhouse Capital’s statement makes little sense.

“The proceeds will be used for clinical trials of GaM (adult and pediatric) and the Expanded Access Program. Additionally, the funds will support and accelerate organic growth, including the completion of the release of IB Clinic and IB Nimble, as well as the expansion of the marketing and sales teams.”

Are we supposed to believe that the latter could be achieved from £250K minus the usual deductions?

Howdlep.

I was still writing my last post when your reply was posted. Thank you for the additional clarification which has moved me forward in my understanding of what might be happening?

ATB.

Howdlep,

Many thanks for your clear explanation. It is much appreciated.

Should the company eventually be sold on at a higher share price than today’s low value, BRH will still achieve a greater return as a result of their increased shareholding. This is what confused me earlier.

There is still hope for investors here, although I was previously thinking in terms of a partnership deal with a large entity, or something similar? That seemed a reasonable way forward given the company’s RNSs and optimism earlier this year?

I cannot see how raising a tiny amount of capital, at significant dilution, can be of much value to IQ-AI/IB or its investors? We shall have to remain patient and see what develops?

Thanks again, and ATB.